سعر ايريلزي 25مجم 4 سرنجة 2026

Erelzi 25 mg (etanercept) solution for injection in pre-filled syringes, pack of 4, by Sandoz.

• Moderate to severe active rheumatoid arthritis (with methotrexate, or as monotherapy when methotrexate is inappropriate), and severe active progressive RA in adults not previously treated with methotrexate.Population: AdultsEuropean Medicines Agency (EMA) – EPAR product information
• Juvenile idiopathic arthritis: polyarthritis or extended oligoarthritis from age 2 years; psoriatic arthritis and enthesitis-related arthritis from age 12 years (after inadequate response to or intolerance of conventional therapy).Population: Children and adolescentsEuropean Medicines Agency (EMA) – EPAR product information
• Active and progressive psoriatic arthritis in adults with inadequate response to DMARDs.Population: AdultsEuropean Medicines Agency (EMA) – EPAR product information

• Most commonly reported adverse reactions: injection-site reactions (pain, swelling, itching, reddening, bleeding), infections (upper respiratory infections, bronchitis, bladder and skin infections), headache, allergic reactions, development of autoantibodies, itching and fever.International label, same product · European Medicines Agency (EMA) – EPAR product information

• Hypersensitivity to etanercept or any excipient.International label, same product · European Medicines Agency (EMA) – EPAR product information
• Sepsis or risk of sepsis.International label, same product · European Medicines Agency (EMA) – EPAR product information
• Active infections, including chronic or localised infections – treatment should not be initiated.International label, same product · European Medicines Agency (EMA) – EPAR product information

• Serious infections, sepsis and opportunistic infections (including invasive fungal infections) have been reported; evaluate for infection before, during and after treatment and discontinue if a serious infection develops.International label, same product · European Medicines Agency (EMA) – EPAR product information
• Tuberculosis: screen for active and inactive (latent) TB before starting; do not start in active TB.International label, same product · European Medicines Agency (EMA) – EPAR product information
• Hepatitis B reactivation in carriers (test for HBV before starting) and worsening of hepatitis C.International label, same product · European Medicines Agency (EMA) – EPAR product information

• AnakinraHigher rate of serious infections and neutropenia without added clinical benefit; combination not recommended.European Medicines Agency (EMA) – EPAR product information
• AbataceptIncreased incidence of serious adverse events without added benefit; combination not recommended.European Medicines Agency (EMA) – EPAR product information
• SulfasalazineStatistically significant decrease in mean white blood cell counts when added to sulfasalazine; use with caution.European Medicines Agency (EMA) – EPAR product information

• Women of childbearing potential should use appropriate contraception during treatment and for three weeks after discontinuation. Etanercept crosses the placenta; use in pregnancy only if clearly needed. Infants exposed in utero may be at increased risk of infection, and live vaccines are not recommended until 16 weeks after the mother's last dose.International label, same product · European Medicines Agency (EMA) – EPAR product information
• Etanercept is excreted in human milk at low levels and poorly absorbed by the infant; use during breastfeeding could be considered, weighing benefits for child and mother.International label, same product · European Medicines Agency (EMA) – EPAR product information

• Etanercept: Competitively inhibits TNF binding to its cell-surface receptors, preventing TNF-mediated cellular responses (EU SmPC 5.1).